INTRODUCTION
Rheumatoid arthritis (RA) describes a relatively novel term defining one of the most common inflammatory arthropathies. It affects roughly 1% of the white population, and its incidence peaks in middle-aged women [1] . Some ethnic groups, particularly those belonging to various Native American tribes, have a strikingly high prevalence of the disease, leading to the speculation that RA is rather a disease of the New World that has been 'transmitted' to other populations after the Conquest [2, 3] . Genes have been implicated, but the current discoveries by genome-wide association studies can only explain about a quarter of the disease variance [4 && ]. Further, studies [5] [6] [7] in monozygotic twins revealed a concordance rate of up to 15%, suggesting that environmental or epigenetic factors or both are required for clinically evident RA. Anticitrullinated peptide antibodies (ACPAs) are immunoglobulins highly specific for the diagnosis of RA and are markers for worse prognosis and disease progression [8] . Intriguingly, they are detectable in circulation many years prior to the development of clinically classifiable RA (i.e. preclinical phase of disease) [9] . During this phase, curiously, the synovial architecture shows no signs of inflammation or immune cell activation [10 && ]. This, coupled with the fact that ACPA and cytokine titers only rise just a few months prior to clinical arthritis [11 & ], has led to many investigators to propose that there must be a 'second hit' beyond the mere presence of humoral autoimmunity in order to trigger the synovitis phase of RA.
Many environmental factors have been contemplated in RA pathogenesis over time [12] . Chief among those is tobacco smoking [13] . Recent epidemiological data support this association, particularly in the context of genetic predisposition and seropositivity [14] . The mechanistic reasons behind this connection are likely multifactorial, but a plausible explanation may relate to the deleterious effects of tobacco and other substances in mucosal sites, particularly in the periodontium and distal airways. In this review, we will cover the most current knowledge on smoking as a risk factor for both progressive disease (PD) and RA, periodontal disease pathogenesis (and its microbiota changes) and RA development.
THE HEALTHY PERIODONTAL MICROBIOME
The oral cavity harbors billions of bacteria and ranks second in total microbial load when compared with the human gut and other body sites. Over 1000 species or phylotypes have been detected in the oral cavity by our group and others [15,16 & ].
Early observations employing 16S rRNA genesequencing evaluated the oral microbiome of clinically healthy individuals [17] . Biofilm samples from subgingival sites with no signs of disease or inflammation (gingival sulci) were obtained. Whereas several species of Streptococcus and Gemella were often found, species associated with periodontal disease, such as Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola, could not be detected. Other studies [18, 19] have identified these putative periodontal pathogens in healthy gingival tissues, although at low levels.
Interestingly, the microbiome diversity of the healthy oral cavity is dependent on geographic localization. Examination of healthy gingival sulci has unraveled a distinct predilection of Streptococci at high levels for the vestibular gingival sulci and of Fusobacterium for the lingual gingival sulci [20] . These differences are related to the oxygen conditions, which are lower for the lingual sites, leading to selection for anaerobic species such as Fusobacterium. Conversely, oxygen levels in the vestibular sites are higher, providing a biologically stable environment for aerobes or facultative anerobes such as Streptococci. This fact underscores the need to sample multiple sites when studying the subgingival microbiome.
Other studies using 454-pyrosequencing suggested that the relative abundance of Actinomyces was higher in health when compared with PD patients [21] . Finally, a study [22] employing a small number of periodontally healthy individuals confirmed previous studies showing that gram-positive genera such as Streptococcus, Actinomyces, and Granulicatella were significantly enriched in healthy periodontal samples. Moreover, this study looked at the functional potential of the healthy periodontal microbiome. A limited number of pathways were significantly enriched in the periodontally healthy microbiome including pathways for fatty acid biosynthesis, purine metabolism, and glycerol-3phosphate metabolism. Fatty acids in particular have been shown to have a protective role in periodontal health, suggesting that some of these metabolites are synthesized by the healthy microbiota in an effort to protect against periodontopathic taxa.
SMOKING AND PERIODONTAL DISEASES
Tobacco smoking is an established and modifiable risk factor for periodontal inflammation and destruction [23] . Similarly, smoking has a negative impact on several inflammatory diseases, including RA, multiple sclerosis, and inflammatory bowel disease [24] .
KEY POINTS
Genetic risk alleles in RA have been extensively studied, although they can only explain a fraction of the total disease variance.
Environmental factors implicated in RA include smoking and chronic infections.
Periodontal diseases and the microbes harbored in the dental plaque, particularly Porphyromonas gingivalis and the elicited humoral immune response, appear to have a pathogenic role.
The oral microbiota and its local and systemic effects in health and disease are being elucidated.
A combination therapeutic approach using DMARDs and nonsurgical PD treatment may improve RA outcomes.
The epidemiology of the effects of tobacco smoking on periodontal health and possible associated mechanisms has been extensively reviewed [25, 26] and is beyond the scope of this article. Evidence for the association between smoking and destructive periodontitis is apparent in several crosssectional studies. The strength of these associations derives from one of the largest studies involving over 1300 individuals [27] . Participants who smoked were at greater risk for experiencing severe bone loss compared with never smokers. Light and heavy smokers exhibited odds ratios for PD of 3.35 and 7.8, respectively. A more recent study [28] based on 12 239 participants in NHANES III database corroborated earlier findings and showed that current smokers were four times more likely to be diagnosed with destructive periodontitis than nonsmokers and that a dose-response could be demonstrated.
Longitudinal studies [29] [30] [31] [32] have also provided evidence of the relationship of smoking and PD in young and older adults alike, demonstrating that tooth loss, bone loss, and attachment loss significantly increased over time in smokers when compared with nonsmokers. Interestingly, the periodontal health condition in former smokers is similar to that of nonsmokers and remains stable over time, suggesting that smoking cessation can reverse at least partially periodontal homeostasis.
OBSERVATIONS OF THE EFFECTS OF SMOKING ON THE SELECTION OF PERIODONTAL PATHOGENS
Periodontal diseases are chronic polymicrobial infections that lead to local inflammatory reactions mediated by antigenic challenges. Evaluation of how microbes activate the immune system in the periodontal tissues is possible through sampling of subgingival periodontal biofilms. Available data related to the effects of smoking on the selection of periodontal pathogens suggest that smokers may harbor a putative periodontal pathogenic flora. Early observations using culture-dependent methods showed that P. gingivalis, Tannerella forsythia, and Aggregatibacter actinomycetemcomitans were more prevalent in smokers than in nonsmokers [33] . Others have studied the effects of smoking on selected periodontal pathogens in periodontal patients [34] . Using logistic regression analysis, one group revealed that smoking and specific measures for PD (i.e. increased periodontal probing depth) significantly correlated with the detection of A. actinomycetemcomitans, Prevotella intermedia, and Eikenella corrodens. Employing real-time PCR, Teixeira et al. [35, 36] have also demonstrated a positive dose-response relationship between smoking and levels of putative periodontal pathogens, most notably P. gingivalis.
These findings have been somehow controversial, as others have reported no differences between smokers and nonsmokers with respect to the detection of periodontal pathogens [37, 38] in terms of prevalence [39] and microbial load [34] in the subgingival domain.
A more recent study [40] looked at the subgingival microbiota of current and never smokers with PD using 16S sequencing. The microbial profile of smoking-associated PD was distinct from that of nonsmokers, with significant differences in the prevalence and abundance of multiple organisms, including increases in pro-periodontopathic taxa such as Parvimonas, Fusobacterium, and Treponema. Taken together, these studies suggest that smoking can be associated with a specific microbial signature independently of PD status.
SMOKING AND RHEUMATOID ARTHRITIS
Tobacco smoking is perhaps the best-established environmental risk factor for RA development [41] [42] [43] . A recent meta-analysis has corroborated this relationship, particularly in those patients who are seropositive and heavy smokers [44] .
Population-based case-control studies [43] have shown that smokers have twice the risk of developing seropositive RA when compared with never smokers. This association appears to be dose-dependent on lifetime exposure to smoking [45 & ,46]. As discussed, compelling evidence has also shown strong gene-environment interactions between smoking and human leukocyte antigen (HLA)-containing shared epitope alleles (HLA-DR SE) [47] . This gene-smoking interaction appears to markedly influence the development of anticitrulline antibody (ACPA)-positive RA [48] . This interaction, however, cannot be demonstrated in patients with ACPA-negative RA. Notably, antibodies against citrullinated peptides are found in sera from patients with aggressive PD without arthritis [49] , although a gene-environment interaction between HLA-DR SE genes and chronic PD has not been reported.
Little is known about the effects of smoking cessation on future risk of RA. A recent study [50] in women showed that the risk of RA decreases over time after smoking cessation. However, when former smokers were compared with never smokers, the risk was still statistically significantly higher. Interestingly, investigators have also been able to show effects of smoking cessation on the gut microbiome [51] . Marked shifts in the microbial composition after smoking cessation could be demonstrated with an increase of Firmicutes and Actinobacteria and lower proportions of Bacteroidetes and Proteobacteria. In addition, an increase in microbial diversity could be observed after smoking cessation. This could explain, at least partially, why smoking exacerbates Crohn's disease. Whether these shifts in the gut microbiome after smoking cessation translates into decreased risk for RA remains to be established.
THE MICROBIOME IN PERIODONTAL DISEASE
A classical study [52] in the field of periodontology looked at bacterial complexes involved in PD, based on microbial analyses of 185 individuals in over 13 000 subgingival plaque samples. The results showed unequivocally that higher levels of P. gingivalis, T. forsythia, and T. denticola in dental plaque are strongly associated with periodontal disease. Since then, this group of microorganisms has been termed the 'red complex bacteria' and numerous studies have replicated these findings.
The subgingival microbiome of diseased and healthy sites was also evaluated by 16S rRNA sequencing in PD and controls [15] . The relative abundance of 51 of 170 genera and 200 of 746 species were found to be significantly different between healthy and diseased sites. Within the deep sites, several species implicated in the original PD studies exhibited significant increases. This was particularly true for P. gingivalis, Porphyromonas endodontalis, Fusobacterium nucleatum, Prevotella nigrescens, Treponema denticola, Treponema medium, and Tannerella forsythia.
PERIODONTAL DISEASE, SUBGINGIVAL MICROBIOTA, PORPHYROMONAS GINGIVALIS, AND RHEUMATOID ARTHRITIS
The concept that PD is implicated in RA pathogenesis is not original. In the early days of the 20th century, the 'oral sepsis' hypothesis was proposed to involve apical infections of the teeth in the cause of RA [53] . This led to the use of dental extraction as a therapeutic option, which went on for at least four decades until it was eventually deemed not clinically beneficial. A more refined and complex hypothesis was suggested a decade ago by Rosenstein et al. [54] , who proposed that it was actually the humoral immune response to P. gingivalis what provided a stimulus for the development of RA. Multiple recent lines of investigation have supported this relationship between PD, P. gingivalis, ACPA, and RA [55] . First, several studies [56,57 && ,58,59] have shown an increased prevalence of PD in RA patients, even at the onset of disease, arguing for either a causal relationship or a common etiopathogenic pathway or both. Second, it has been postulated that ACPA generation is the result of citrullination of arginine residues in human tissues by the enzyme peptidyl arginine deiminase (PAD). This is of particular importance because P. gingivalis is reportedly the only bacterial species that carries PAD as part of its enzymatic machinery. Notably, P. gingivalisderived PAD is able to citrullinate human peptides [60] , whereas human citrullinated peptides (such as alpha-enolase) are sufficient for triggering inflammatory arthritis in animal models [61] . Moreover, the presence of antibodies to P. gingivalis has also been correlated with autoimmunity (i.e. circulating ACPA) and clinical RA. This is not only true for patients with established RA [62] [63] [64] , but also in individuals at-risk for disease development (i.e. firstdegree relatives) [65] . However, the demonstrated prevalence of such humoral response has been variable, mostly because of the heterogeneity of the assays employed in the different studies [66] . Finally, only a handful of reports looked at the presence of P. gingivalis (or other microorganisms) in subgingival biofilms of patients with RA. With the use of high-throughput, bacterial DNA sequencing, we have shown that about 55% of new-onset, untreated RA patients carried P. gingivalis, twice as many as healthy controls [57 && ]. This difference did not reach statistical significance and was mostly because of the high prevalence of the advanced forms of PD in the RA groups, rather than secondary to arthritis phenotype. These findings suggest that while both PD and the presence of P. gingivalis may promote autoantibody formation in RA, only PD demonstrates an independent relationship with established seropositive RA (both in the new-onset and the chronic phases of the disease). Utilizing lowthroughput PCR technology, Mikuls et al. [67 && ] have recently validated these observations in a large case-control study. A smaller study by Wolff et al. [68] reported similar clinical associations in early RA patients and a trend toward P. gingivalis increase.
Interestingly, we and others have identified additional bacterial species that correlate with either RA-related autoantibodies (Anaeroglobus geminatus) or early RA (i.e. Prevotella, Leptrotrichia, and Tannerella species). This reinforces the notion that RA may require other antigenic triggers in the context of PD, as recently demonstrated by Abdollahi-Roodsaz et al. [69] , using a murine model of PD and RA in which both P. gingivalis and Prevotella nigrescens were able to promote subgingival and synovial inflammation, albeit through different immune mechanisms.
PERIODONTAL DISEASE TREATMENT AS ADJUVANT FOR DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
Scaling and root planning remain the mainstay of therapy for PD. It consists of a nonsurgical process aimed at eliminating the etiologic agents of PD, namely dental plaque, its products, and calculus formation. If in fact PD is at least partially responsible for the systemic inflammatory process found in RA, then it follows that scaling and root planning should help ameliorate synovitis and disease outcomes. To date, only a few relatively small studies have looked at this hypothesis. One of the first such trials evaluated disease outcomes in 20 individuals with RA on background disease-modifying antirheumatic drugs (DMARDs) and 20 receiving DMARDs and anti-TNF treatment [70] . Each of the groups was randomized to either scaling/root planning or no PD treatment. Patients who received PD treatment showed a significant decrease in DAS28, erythrocyte sedimentation rate, and serum tumor necrosis factor alpha (TNF-a) levels compared with those without PD therapy. Curiously, anti-TNF therapy also resulted in a significant improvement in clinical PD parameters. These findings have also been corroborated independently in different geographic regions [71] [72] [73] . In a recent prospective study [74 && ] on RA patients about to undergo anti-TNF treatment, it was shown that the presence of persistent PD hampered the clinical response to TNFblockade since only those patients without established periodontitis achieved good RA outcomes.
Taken together, these studies support the notion that PD may affect treatment efficacy in patients with RA and that a dual, combination approach may be warranted to potentially increase the clinical response of various immunosuppressive drugs.
CONCLUSION
The role of tobacco smoking in PD was established many decades ago. Emerging epidemiologic and mechanistic work is now revealing that smoking is also a risk factor for the development of RA, particularly in the ACPA-positive, SE-positive subset. An association between tobacco, PD, presence of P. gingivalis, and RA has been strengthened by multiple lines of research, particularly with the advent of novel bacterial DNA sequencing technologies that bypass the need for classic microbiologic culture methods. Because smoking and PD are readily modifiable contributing factors to RA pathogenesis, it is plausible that a multidisciplinary approach to treatment may hold the key for achieving better outcomes in more patients with RA. Small-scale data support the potential utility for such an approach. A large, randomized, clinical trial will be therefore required to address this highly relevant question. Incorporating periodontal microbiota analyses and RA/PD outcomes will also be necessary in order to better understand the biologic connection between these two seemingly interdependent disease processes.
